Stonepine Capital Management LLC Makes New $394,000 Investment in Septerna, Inc. $SEPN

Key Points

• Stonepine Capital Management LLC invested $394,000 in Septerna, Inc., acquiring approximately 68,084 shares, representing 0.15% of the company's stock.
• Septerna's recent earnings report showed a significant loss of ($0.56) EPS, missing estimates and a stark revenue of $0.12 million compared to forecasts of $22.50 million.
• Analysts have mixed views on Septerna's stock, with a price target ranging up to $26.00 and ratings varying from "buy" to "sell", indicating divided opinion on the stock's future performance.

Stonepine Capital Management LLC acquired a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 68,084 shares of the company's stock, valued at approximately $394,000. Stonepine Capital Management LLC owned 0.15% of Septerna at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in Septerna in the fourth quarter worth about $1,803,000. JPMorgan Chase & Co. purchased a new stake in Septerna in the fourth quarter worth about $871,000. Jane Street Group LLC purchased a new stake in Septerna in the fourth quarter worth about $600,000. MetLife Investment Management LLC purchased a new stake in Septerna in the fourth quarter worth about $265,000. Finally, Barclays PLC purchased a new stake in Septerna in the fourth quarter worth about $659,000.

Septerna Price Performance

NASDAQ:SEPN traded down $0.07 during midday trading on Wednesday, hitting $12.63. The company's stock had a trading volume of 195,700 shares, compared to its average volume of 231,341. Septerna, Inc. has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The firm's 50 day moving average is $11.72 and its 200-day moving average is $8.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. On average, sell-side analysts forecast that Septerna, Inc. will post -7.11 EPS for the current year.

Wall Street Analysts Forecast Growth

SEPN has been the subject of a number of research reports. Wall Street Zen lowered shares of Septerna from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. HC Wainwright reissued a "buy" rating and set a $26.00 price target on shares of Septerna in a research report on Thursday, August 21st. Cantor Fitzgerald increased their price target on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Finally, Wells Fargo & Company increased their price target on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Septerna presently has an average rating of "Moderate Buy" and an average target price of $26.75.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.